Modern Medicine News

Harnessing laziness to do goodMany maintain that rising early, getting to work, accomplishing a lot during the day, and getting to bed at a reasonable hour is the route to success in life. But a body of evidence suggests that human behavioral tendencies to do too much, in some cases, can reduce the likelihood of a good result. At the same time, laziness can produce outcomes that are either negative or positive.
Phaco turns 50
Phaco turns 50As the ophthalmic community celebrates 50 years of phacoemulsification (phaco) innovation, surgeons and industry alike mark its progress since the inspiration for the procedure came to Charles Kelman, MD, after a visit to the dentist.
Independence and optimizing your practiceNo matter how you celebrated the 4th, you can have your own “freedom day” in your practice starting today! What this means is you have the freedom to be your best, every single day of the year.
What is the price of a medical record?
What is the price of a medical record?While all of us recognize the advantages of an electronic record in the respect of data retrieval, the risk has become greater because many practices do not secure their network.
Welcome to the 2017 Glaucoma 360Adrienne Graves, PhD, and Andrew Iwach, MD, welcome attendees to Glaucoma 360 with their focus set on next year's conference, February 9, 2018 in San Francisco.
CMS lowers estimates for MIPS compliance requirements
CMS lowers estimates for MIPS compliance requirementsThe Centers for Medicare and Medicaid Services (CMS) has notified more than 800,000 healthcare providers that they do not have to comply with the Merit-based Incentive Payment System in 2017.
Eric Schweiger, M.D., named award semifinalist
Eric Schweiger, M.D., named award semifinalistEric Schweiger, M.D., C.E.O., and founder of the Schweiger Dermatolo- gy Group, has been named a semifinalist for the EY Entrepreneur of the Year 2017 Award for the New York region, according to a news release.
Abatacept: Pricey, but Effective
Abatacept: Pricey, but EffectiveThe approval of abatacept (Orencia/Bristol-Myers Squibb) for psoriatic arthritis (PsA) earlier this month by the FDA offers a new treatment option for patients who are struggling to keep the disease under control.
Death of the pressure patch has been slightly exaggerated
Death of the pressure patch has been slightly exaggeratedBest practice guidelines are just that—guidelines. They’re not religious dogma designed to herd everyone into the same line. We are rightly moving toward more evidence-based medicine, such as increased use of bandage lenses and less pressure patching in the management of corneal abrasions and erosions.
New products: Holmium laser increases stone ablation volumeOther products discussed include cancer tests, an app to connect patients with specialists, a revenue management system, and more